Currenc Group Inc

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.

NEW YORK, Sept. 26, 2024 (GLOBE NEWSWIRE) -- CURRENC Group Inc. (Nasdaq: CURR) (“CURRENC” or the “Company”), a fintech and digital remittance pioneer serving millions of unbanked and underbanked individuals in Southeast Asia and beyond, today announced that the Company's management celebrated its recent listing with a Closing Bell Ceremony at Nasdaq MarketSite in Times Square this afternoon. CURRENC began trading on the Nasdaq on September 3, 2024, after completing its business combination with INFINT Acquisition Corporation (formerly NYSE: IFIN), which was facilitated by ARC Group Limited.

CURRENC Rings Nasdaq Closing Bell in Honor of Listing

New Campaigns Showing Encouraging Results SHERMAN OAKS, CA / ACCESSWIRE / August 15, 2023 / Avenir Wellness Solutions, Inc. (OTC PINK:AVRW) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the second fiscal quarter ended June 30, 2023. Key operational highlights for the second quarter included the following: Net revenue in the second quarter of 2023 decreased slightly year-over-year and sequentially from Q1 2023 to $1.0 million due to the delay in receiving the expected remainder of the asset sale proceeds as well as manufacturing delivery delays due to raw material supply shortages.

Avenir Wellness Solutions Reports Second Quarter 2023 Results

New Branding Reflects Company's Commitment to the Future of Wellness SHERMAN OAKS, CA / ACCESSWIRE / August 8, 2023 / Avenir Wellness Solutions, Inc. (OTC Pink:CURR) ("Avenir" or the "Company"), a proprietary broad platform and wellness technology company, today announced that it has received regulatory approval to officially change its ticker symbol from "CURR" to "AVRW" effective at the stock market opening on August 9, 2023. The ticker symbol change follows the corporate name change to "Avenir Wellness Solutions, Inc." in October 2022.

Avenir Wellness Solutions Announces New Ticker Symbol As Final Part of Exciting New Brand Identity

New Product Showing Encouraging Early Results SHERMAN OAKS, CA / ACCESSWIRE / July 31, 2023 / Avenir Wellness Solutions, Inc. (OTC:CURR) ("Avenir" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the quarter ended March 31, 2023. Key operational highlights for the first quarter included the following: Net revenue in the first quarter of 2023 increased 15.1% year-over-year and 35.6% sequentially from Q4 2022 to $1.2 million with further increases expected in the second half of the year.

Avenir Wellness Solutions Reports First Quarter 2023 Results with Strong Sequential and Year Over Year Revenue Increases and Continued High Gross Margins

Company's stock trading moved from OTCQB to OTC Pink Market for late filing of 2022 Annual Report due to auditor change - Company to re-apply to OTCQB when filings made current Pre-sales and initial sales of new transformational product DNA Complex exceeding expectations with extensive coverage of award-winning Actress Nicole Kidman's use of the product at the Oscars, Met Gala and Academy of Country Music Awards SHERMAN OAKS, CA / ACCESSWIRE / May 17, 2023 / Avenir Wellness Solutions, Inc. ("Avenir" or the "Company") (OTCQB:CURR), a proprietary broad platform technology and wellness company, is providing the following update to stockholders. As reported in our recent Current Reports on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on April 19-20, 2023, the Company's predecessor auditor, RBSM LLP, resigned on April 12, 2023.

Avenir Wellness Solutions Update to Stockholders

Presentation TODAY at 1:30PM Pacific Time (4:30 PM Eastern Time) SHERMAN OAKS, CA / ACCESSWIRE / April 26, 2023 / Avenir Wellness Solutions, Inc. ("Avenir Wellness") (OTCQB:CURR), a proprietary broad platform technology and wellness company, announced today that it will be presenting at the Planet MicroCap Showcase TODAY Wednesday, April 26, 2023, at 1:30 PM Pacific Time (4:30 PM Eastern Time). The Company's CEO, Nancy Duitch, will be presenting.

Avenir Wellness Solutions (OTCQB:CURR) to Present at the Planet MicroCap Showcase - Live Webcast Available

Extended Contract with theSkimm Social Media Network Reaching 7 Million Loyal Subscribers Highly Regarded Urish Popeck & Co., LLC Engaged as New Independent Registered Public Accounting Firm Marketing Program Expansions Including New TV Ads to Support Sales at Major Retailers of Amazon and Walmart Gleaming Facial Dark Spot Fading Serum Used by Award winning Actor Nicole Kidman Delivering 77% Subscription Retention Rate SHERMAN OAKS, CA / ACCESSWIRE / April 25, 2023 / Avenir Wellness Solutions, Inc. ("Avenir Wellness") (OTCQB:CURR), a proprietary broad platform technology and wellness company, is pleased to provide the following update letter to stockholders from CEO Nancy Duitch. Dear Avenir Stockholders: As we move forward into 2023, the Company is poised for major growth as we laid down the foundation and go-forward strategy to fully develop the Company's new business model for our proprietary wellness, nutraceutical and advanced delivery methods.

Avenir Wellness Letter to Stockholders

The Most Scientifically Advanced Wrinkle Remover on The Market SHERMAN OAKS, CA­­ / ACCESSWIRE / March 16, 2023 / Avenir Wellness Solutions, Inc. (f/k/a CURE Pharmaceutical Holding Corp.) ("Avenir Wellness") (OTCQB:CURR), a proprietary broad platform technology and wellness company, today announced that its subsidiary The Sera Labs, Inc. ("Sera Labs") has launched its latest innovation in the Seratopical Revolution skincare line: DNA (Deep Nano Actives) Complex , an instant anti-aging skin tightening serum that penetrates deep into the skin. Sitting at the intersection of skin science and nature, DNA Complex begins working from the moment it's applied to your face and neck.

Avenir's Sera Labs Launches Patent Pending DNA Complex with Advanced Peptides and Compounds - Providing Instant and Long-Lasting Results With Daily Use

Brand Ambassador Nicole Kidman Featured in Postings on theSkimm SHERMAN OAKS, CA / ACCESSWIRE / February 13, 2023 / Avenir Wellness Solutions, Inc. (f/k/a CURE Pharmaceutical Holding Corp.) (OTCQB:CURR), a proprietary broad platform technology and wellness company ("Avenir" or the "Company"), is pleased to announce that its Sera Labs informational postings are now appearing on theSkimm social media platform which covers a wide range of trending topics with its daily newsletter distributed to over 7 million followers. The Sera Labs posts on theSkimm feature eye-catching photos of its Brand Ambassador Nicole Kidman with commentary on the Company's advanced Seratopical Revolution beauty, anti-aging and wellness product lines.

Avenir Wellness Solutions, Inc. Gains High Profile Exposure on theSkimm Social Media Platform With 7 Million Followers and Launches New Website in Support of Corporate Rebranding

SHERMAN OAKS, CA / ACCESSWIRE / January 19, 2023 / Avenir Wellness Solutions, Inc. (f/k/a CURE Pharmaceutical Holding Corp.) (OTCQB:CURR), a proprietary broad platform technology and wellness company ("Avenir" or the "Company") announced that it is launching an informational series to inform the Wall Street community about its unique dual revenue model involving breakthrough consumer wellness products and intellectual property monetization. Avenir has retained producer New to The Street to create sponsored television content featuring Avenir's leadership that will be nationally and internationally syndicated on major television networks.

Avenir Wellness Solutions to Launch Wall Street-focused Informational Series with Producer New to The Street

New branding reflects Company's commitment to the future of wellness SHERMAN OAKS, CA / ACCESSWIRE / January 17, 2023 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) ("CURE" or the "Company"), a proprietary broad platform and wellness technology company, today announced that it has changed its name to "Avenir Wellness Solutions, Inc." ("Avenir Wellness") which will be the name for the company as a corporate entity. The name change is the result of the Company's recent sale of certain intellectual property.

CURE Pharmaceutical Unveils Exciting New Brand Identity with Name Change to Avenir Wellness Solutions, Inc.

Investment in New Marketing Strategies Showing Encouraging Early Results Enhanced Instagram & Media campaigns featuring Nicole Kidman highlighting Seratopical Revolution Incubator Strategy Initiated with New Market Disruptor Products arriving 1H2023 SHERMAN OAKS, CA / ACCESSWIRE / December 15, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) CEO Nancy Duitch is providing an update to its shareholders on positive recent developments in the evolution and progress of the Company. Dear Shareholders: We would like to thank all of you for your continued support during this exciting time in our company's history.

CURE Pharmaceutical Letter to Shareholders

New Marketing Programs Showing Encouraging Early Results SHERMAN OAKS, CA / ACCESSWIRE / November 22, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) ("CURE" or the "Company"), a proprietary broad platform technology and wellness company, today announced results for the quarter ended September 30, 2022. Key operational highlights included the following: Revenue in the third quarter surged 32.1% year-over-year and 58.9% sequentially from Q2 2022 to $1.8 million with further increases expected in Q4.

CURE Pharmaceutical Reports Third Quarter 2022 Results With Strong Sequential and Year Over Year Revenue Increases and Continued High Margins

Sherman Oaks, California--(Newsfile Corp. - November 10, 2022) - Avenir Wellness Solutions, Inc. (f/k/a CURE Pharmaceutical Holding Corp.) (OTCQB: CURR) today announced that CEO Nancy Duitch will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square.

Avenir Wellness Solutions to Present at Investor Summit Group's Q4 Conference

Presentation on Tuesday, October 25 at 12:30 PM Pacific Time (3:30 PM Eastern)Oxnard, California--(Newsfile Corp. - October 24, 2022) - Cure Pharmaceutical Holding Corp. (OTCQB: CURR) ("CURE"), a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems, announced today that it will be presenting at the 12th annual Invitational on Tuesday October 25 at 12:30 PM Pacific Time (3:30 PM Eastern) at the Luxe Sunset Boulevard Hotel. Nancy Duitch, CEO will be giving the presentation.

Cure Pharmaceutical Holding to Present at the LD Micro Main Event XV

Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments

Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins

Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience.

CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman

OXNARD, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive management team provided details on the recent $20 million non-dilutive sale of a portion of its product and intellectual property portfolio and provided a full business update.

CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call

Gerald Bagg brings deep understanding of CPG to CURE Gerald Bagg brings deep understanding of CPG to CURE

CURE Pharmaceutical Announces the Appointment of New Board Member

Updates on Recent Transaction and Business will be Provided Updates on Recent Transaction and Business will be Provided

CURE Pharmaceutical Announces Teleconference With Investors

Proceeds Will Be Used to Grow CURE's Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology Proceeds Will Be Used to Grow CURE's Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology

CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million

OXNARD, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CURE Pharmaceutical Holdings (OTC: CURR), a developer and manufacturer of innovative delivery formulations for drugs, supplements and wellness products, today announced positive finding from a study conducted at Cincinnati Children's Hospital Medical Center (CCHMC) using CURE's proprietary, single dose, oral, 40,000 IU vitamin D (branded ImmunD3™ Nutri-Strips™ in the retail wellness market) in pediatric patients before stem cell therapy. CURE's oral Vitamin D supplement was found to be more effective than standard supplementation in achieving pre- and post-surgery vitamin D sufficiency, which is critical for reducing immune-mediated organ damage in the children receiving HSCT.

CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children's Hospital Medical Center (CCHMC) Using CURE's Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Tran

COFEPRIS (Mexico's equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE's Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE's patented Oral Thin Film (OTF) dose form CUREform™ COFEPRIS (Mexico's equivalent of the US FDA) grants authorization for the manufacture, distribution and sale in Mexico of CURE's Sildenafil, Vitamin D3, Electrolyte, Energy, and Sleep products in CURE's patented Oral Thin Film (OTF) dose form CUREform™

CURE Pharmaceutical and Milagro Pharmaceuticals Collaborate for Registration and Approval to Sell Sildenafil Oral Thin Film in Mexico

Northern Response International To Distribute Seratopical Revolution® Masstige Line Northern Response International To Distribute Seratopical Revolution® Masstige Line

Sera Labs, a Subsidiary of CURE Pharmaceutical, Consummates Exclusive International Distribution Agreement With Leading Canadian Distributor

OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the '331 patent) is set to issue on November 23, 2021. The '331 patent, entitled “Oral Soluble Film Containing Sildenafil Citrate,” cov

News for Currenc Group Inc Stock (CURR)